ORKA
Oruka Therapeutics, Inc.
NASDAQ: ORKA · HEALTHCARE · BIOTECHNOLOGY
$104.99
-2.03% today
Updated 2026-11-12
Market cap
$6.92B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.08
Dividend yield
—
52W range
$25 – $116
Volume
1.0M
WallStSmart proprietary scores
25
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C8.0
Quality
A3.0
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
16.5
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →259 stocks currently score above 75
Price targets
Analyst target
$156.17
+48.75%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy11 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 16.52 — safe zone
+ Debt/equity 0.00x — low leverage
Risks
- Piotroski 1/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-33.15M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | $0.00 |
| Net income | $-9.93M | $-5.34M | $-83.72M | $-105.43M | $-41.21M |
| EPS | — | — | — | — | $-2.08 |
| Free cash flow | $-18.80M | $-10.91M | $-58.03M | $-88.42M | $-33.15M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Oruka Therapeutics, Inc. trades at $104.99. Our Smart Value Score of 25/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of 16.52, it sits in the safe zone.
Frequently asked questions
What is Oruka Therapeutics, Inc.'s stock price?
Oruka Therapeutics, Inc. (ORKA) trades at $104.99.
Is Oruka Therapeutics, Inc. overvalued?
Oruka Therapeutics, Inc. carries a Smart Value Score of 25/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Oruka Therapeutics, Inc. (ORKA)?
The 12-month analyst consensus target is $156.17, about 48.7% above the current $104.99. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Oruka Therapeutics, Inc.'s Altman Z-Score is 16.52, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-23.89%
Beta-0.17
50D MA$88.22
200D MA$70.86
Shares out0.07B
Float0.06B
Short ratio—
Avg volume1.0M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—